These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34581471)

  • 1. Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs*.
    Ramos-Guzmán CA; Ruiz-Pernía JJ; Tuñón I
    Angew Chem Int Ed Engl; 2021 Dec; 60(49):25933-25941. PubMed ID: 34581471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease.
    Ramos-Guzmán CA; Ruiz-Pernía JJ; Tuñón I
    Chem Commun (Camb); 2021 Sep; 57(72):9096-9099. PubMed ID: 34498651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiscale Simulations of SARS-CoV-2 3CL Protease Inhibition with Aldehyde Derivatives. Role of Protein and Inhibitor Conformational Changes in the Reaction Mechanism.
    Ramos-Guzmán CA; Ruiz-Pernía JJ; Tuñón I
    ACS Catal; 2021 Apr; 11(7):4157-4168. PubMed ID: 34192090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
    Ahmad B; Batool M; Ain QU; Kim MS; Choi S
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Se-S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study.
    Parise A; Romeo I; Russo N; Marino T
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
    Refaey RH; El-Ashrey MK; Nissan YM
    Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuning Proton Transfer Thermodynamics in SARS-CoV-2 Main Protease: Implications for Catalysis and Inhibitor Design.
    Zanetti-Polzi L; Smith MD; Chipot C; Gumbart JC; Lynch DL; Pavlova A; Smith JC; Daidone I
    J Phys Chem Lett; 2021 May; 12(17):4195-4202. PubMed ID: 33900080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
    Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
    J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,2,4 triazolo[1,5-a] pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: In silico screening and molecular dynamics simulation of potential COVID-19 drug candidates.
    Kavitha K; Sivakumar S; Ramesh B
    Biophys Chem; 2020 Dec; 267():106478. PubMed ID: 33022567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.
    Banerjee S
    Biophys Chem; 2021 Feb; 269():106510. PubMed ID: 33285430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
    Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
    Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
    Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc
    Panchariya L; Khan WA; Kuila S; Sonkar K; Sahoo S; Ghoshal A; Kumar A; Verma DK; Hasan A; Khan MA; Jain N; Mohapatra AK; Das S; Thakur JK; Maiti S; Nanda RK; Halder R; Sunil S; Arockiasamy A
    Chem Commun (Camb); 2021 Sep; 57(78):10083-10086. PubMed ID: 34514483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease.
    Sur VP; Sen MK; Komrskova K
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of SARS-CoV-2 3CL
    Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
    Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease.
    Macchiagodena M; Pagliai M; Procacci P
    J Mol Graph Model; 2022 Jan; 110():108042. PubMed ID: 34653812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.